Source: Pharmacy Times articles
A phase 2 study showed that elotuzumab combined with pomalidomide, bortezomib, and dexamethasone was safe and efficacious.
Read More
Recent Content
- Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
- Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis
- What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?
- Depression, anxiety prevalent among adults with lymphoma, multiple myeloma
- Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
- Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma
- Quadruplet Regimen Preferable to Triplets in Multiple Myeloma
- Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
- Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
- Daratumumab regimen improves survival in transplant-ineligible multiple myeloma